PAR · ALVIO.PA
Valerio Therapeutics S.A.
€0.51+€0.09 (+22.01%)
Valerio Therapeutics S.A.’s quoted price sits in the lower half of its reported 52-week range, 47.96% below the high.
Loading market information…
PAR · MAAT.PA · EUR
Stock price, earnings
Quote as of Oct 29, 2026, 04:38 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
MaaT Pharma S.A.’s quoted price sits in the lower half of its reported 52-week range, 87.59% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
MaaT Pharma S.A.’s next earnings report is currently expected on Apr 1, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow MaaT Pharma S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
MaaT Pharma SA operates as a clinical-stage biotechnology company, focused on the discovery and advancement of microbiome-based biotherapies, primarily for the treatment of solid cancer tumors. Its development pipeline features MaaT013, which has successfully completed Phase 2 clinical trials for acute graft-versus-host disease (aGVHD) and is also undergoing preclinical evaluation for melanoma. Another therapeutic candidate, MaaT033, is currently in Phase 1b clinical trials, aiming to improve survival outcomes for patients with acute myeloid leukemia (AML) or other liquid malignancies following allogeneic hematopoietic stem cell transplantation. Furthermore, MaaT03X is being developed specifically for solid tumor applications. The company was founded in 2014 and maintains its headquarters in Lyon, France.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2022 | May 9, 2023 | -€0.64 | €936.00K |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€0.51+€0.09 (+22.01%)
Valerio Therapeutics S.A.’s quoted price sits in the lower half of its reported 52-week range, 47.96% below the high.
€2.81€0.00 (0.0%)
Affluent Medical S.A.’s quoted price sits in the upper half of its reported 52-week range, 4.75% below the high.
€8.90+€0.10 (+1.14%)
Sensorion S.A.’s quoted price sits in the lower half of its reported 52-week range, 77.97% below the high.
€0.16+€0.01 (+4.44%)
Klea Holding’s quoted price sits in the lower half of its reported 52-week range, 38.42% below the high.
€0.39-€0.00 (-0.13%)
Fermentalg’s quoted price sits in the lower half of its reported 52-week range, 39.14% below the high.
€0.55+€0.01 (+1.11%)
AB Science S.A.’s quoted price sits in the lower half of its reported 52-week range, 65.96% below the high.
€0.31€0.00 (0.0%)
Nicox S.A.’s quoted price sits in the lower half of its reported 52-week range, 45.52% below the high.
€0.07-€0.00 (-1.07%)
GenSight Biologics S.A.’s quoted price sits in the lower half of its reported 52-week range, 68.91% below the high.
